Halo naevi, vitiligo and diffuse alopecia areata associated with tocilizumab therapy.

Oxf Med Case Reports

University of Leeds, Leeds Institute of Rheumatic and Musculoskeletal Medicine , Chapel Allerton Hospital, Leeds , UK.

Published: August 2016

We present a follow-up case report of a 33-year-old lady with juvenile onset arthritis who developed halo naevi while on treatment with tocilizumab. This case report describes the development of halo naevi, vitiligo and diffuse alopecia areata associated with tocilizumab therapy following infection with Methicillin-resistant Staphylococcus aureus (MRSA) and Panton-Valentine leukocidin positivity. This is the first case that describes these events and supports previous theories on cellular and humoral immunity as causative factors. The regression of melanocytes during treatment with tocilizumab could also implicate IL-6 and sIL-6R as future targets in the treatment of melanoma through its direct effect of melanocytic cytotoxicity, which supports previous studies.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4979291PMC
http://dx.doi.org/10.1093/omcr/omw027DOI Listing

Publication Analysis

Top Keywords

halo naevi
12
naevi vitiligo
8
vitiligo diffuse
8
diffuse alopecia
8
alopecia areata
8
areata associated
8
associated tocilizumab
8
tocilizumab therapy
8
case report
8
treatment tocilizumab
8

Similar Publications

Oral melanocytic nevi (OMN) are rare benign tumors originating from melanocytes with an unclear pathogenesis. The current theory suggests that OMN originate from dormant dendritic melanocytes that become enclosed in the dermis during the embryonic migration of melanoblasts - the precursors of melanocytes - from the neural crest to the epidermis. OMN can be congenital or acquired, with acquired nevi being more common.

View Article and Find Full Text PDF

Diagnosis of nevoid melanoma (NeM) is often difficult because NeM closely resembles a common nevus clinically and histologically. A retrospective study was conducted on 110 patients diagnosed with and/or treated for primary nevoid melanoma at the Veneto Institute of Oncology and at the University Hospital of Padua from August 1999. Mean Breslow thickness was of 1.

View Article and Find Full Text PDF

Glomus Tumor in the Left Submandibular Region: A Rare Case Report and Literature Review.

Cancer Rep (Hoboken)

January 2025

Department of Dermatology, the Fourth Affiliated Hospital of School of Medicine, and International School of Medicine, International Institutes of Medicine, Zhejiang University, Yiwu, China.

Background: Glomus tumors are rare, benign mesenchymal neoplasms predominantly located in subungual regions of the extremities. Their occurrence in the mandibular region is exceptionally uncommon, presenting unique diagnostic challenges. Only a limited number of submandibular glomus tumors have been documented, leaving their presentation and management largely underexplored.

View Article and Find Full Text PDF

AI-assisted Total Body Dermoscopic Evaluation of Changes in Melanocytic Nevi during Pregnancy: A Prospective, Comparative Study of 2,799 Nevi.

Acta Derm Venereol

January 2025

Department of Dermatology, University Hospital of Basel, Basel, Switzerland; Department of Dermatology, University Hospital of Zurich, Zurich, Switzerland; Faculty of Medicine, University of Zurich, Zurich, Switzerland.

Pregnancy-associated changes in melanocytic nevi (MN), apart from size increase on the trunk, remain a topic of debate. We conducted the first prospective study to investigate dermoscopic changes in MN comparing pregnant with non-pregnant women on all body parts using a market-approved convolutional neural network (CNN). We included 25 pregnant and 25 non-pregnant women from Basel, Switzerland, who underwent standard skin cancer screenings and whose MN > 2 mm were digitally recorded and analysed by a CNN.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!